N-terminal polyubiquitination and degradation of the Arf tumor suppressor
AUTOR(ES)
Kuo, Mei-Ling
FONTE
Cold Spring Harbor Laboratory Press
RESUMO
Unknown mechanisms govern degradation of the p19Arf tumor suppressor, an activator of p53 and inhibitor of ribosomal RNA processing. Kinetic metabolic labeling of cells with [3H]-leucine indicated that p19Arf is a relatively stable protein (half-life ∼6 h) whose degradation depends upon the ubiquitin–proteasome pathway. Although p19Arf binds to the Mdm2 E3 ubiquitin protein ligase to activate p53, neither of these molecules regulates p19Arf turnover. In contrast, the nucleolar protein nucleophosmin/B23, which binds to p19Arf with high stoichiometry, retards its turnover, and Arf mutants that do not efficiently associate with nucleophosmin/B23 are unstable and functionally impaired. Mouse p19Arf, although highly basic (22% arginine content), contains only a single lysine residue absent from human p14ARF, and substitution of arginine for lysine in mouse p19Arf had no effect on its rate of degradation. Mouse p19Arf (either wild-type or lacking lysine) and human p14ARF undergo N-terminal polyubiquitination, a process that has not as yet been documented in naturally occurring lysine-less proteins. Re-engineering of the p19Arf N terminus to provide consensus sequences for N-acetylation limited Arf ubiquitination and decelerated its turnover.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=517406Documentos Relacionados
- Giardicidal activity of lactoferrin and N-terminal peptides.
- Enhanced tumor cell growth suppression by an N-terminal truncated retinoblastoma protein.
- Mutations of N-terminal regions render the retinoblastoma protein insufficient for functions in development and tumor suppression.
- Translocation of N-terminal tails across the plasma membrane.
- Gαs is palmitoylated at the N-terminal glycine